A beginner's guide to chemokines.

Abstract:

:This review provides an overview of chemokines and their receptors, with an emphasis on general features and nomenclature along with a short summary of their properties and functions. It is intended as an introduction to the subject and a reference point for those wishing to learn key facts about chemokines and their role in biology.

journal_name

Future Med Chem

authors

Vinader V,Afarinkia K

doi

10.4155/fmc.12.49

subject

Has Abstract

pub_date

2012-05-01 00:00:00

pages

845-52

issue

7

eissn

1756-8919

issn

1756-8927

journal_volume

4

pub_type

杂志文章,评审
  • Ask the experts: future of the pharmaceutical industry. Interview by Future Medicinal Chemistry.

    abstract::The pharmaceutical industry is facing numerous, well-documented challenges - from the effects of patent expirations to high attrition rates in the drug-development pipeline. Future Medicinal Chemistry has invited a group of leaders from academia and industry to express their views on where the industry is heading and ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.11.145

    authors: Cottens S,Eaton M,Fuhr J,Geary S,Johnson DS,Li G,Raveglia L,Robertson GM,Westwell A

    更新日期:2011-11-01 00:00:00

  • Membrane-targeting antibiotics: recent developments outside the peptide space.

    abstract::The rise of antibiotic resistant bacteria requires unconventional strategies toward efficient chemotherapeutic agents, preferably with alternative mechanisms of action. The bacterial cell membrane has become an appealing target since its essential and highly conservative structure are key challenges to resistance mech...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0254

    authors: Dias C,Rauter AP

    更新日期:2019-02-25 00:00:00

  • A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants.

    abstract::The EGFR is one of the most popular targets for anticancer therapies and many drugs, such as erlotinib and gefitinib, have got enormous success in clinical treatments of cancer in past decade. However, the efficacy of these agents is often limited because of the quick emergence of drug resistance. Fundamental structur...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0222

    authors: Guan H,Du Y,Ning Y,Cao X

    更新日期:2017-05-01 00:00:00

  • In silico and saturation transfer difference NMR approaches to unravel the binding mode of an andrographolide derivative to K-Ras oncoprotein.

    abstract::Background: Andrographolide and its benzylidene derivatives, SRJ09 and SRJ23, potentially bind oncogenic K-Ras to exert anticancer activity. Their molecular interactions with K-Ras oncoproteins that lead to effective biological activity are of major interest. Methods & results:In silico docking and molecular dynamics ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0104

    authors: Quah SY,Tan MS,Ho KL,Manan NA,Gorfe AA,Deb PK,Sagineedu SR,Stanslas J

    更新日期:2020-09-01 00:00:00

  • Recent developments and advances of FGFR as a potential target in cancer.

    abstract::FGFs and their receptors (FGFRs) are critical for many biologic processes, including angiogenesis, wound healing and tissue regeneration. Aberrations in FGFR signaling are common in cancer, making FGFRs a promising target in antitumor studies. To date, many FGFR inhibitors are being detected in clinical studies, and r...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0103

    authors: Xue WJ,Li MT,Chen L,Sun LP,Li YY

    更新日期:2018-09-01 00:00:00

  • Indole molecules as inhibitors of tubulin polymerization: potential new anticancer agents.

    abstract::Agents that interfere with tubulin function have a broad anti-tumor spectrum and they represent one of the most significant classes of anticancer agents. In the past few years, several small synthetic molecules that have an indole nucleus as a core structure have been identified as tubulin inhibitors. Among these, sev...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.141

    authors: Patil SA,Patil R,Miller DD

    更新日期:2012-10-01 00:00:00

  • Interview with Chi-Chao Chan. Interview by Isaac Bruce.

    abstract::Chi-Chao Chan, an American board certified ophthalmologist, is the Chief of Immunopathology Section, Laboratory of Immunology and the Head of Histology Core at the National Eye Institute at National Institutes of Health (USA). In 1967, Dr Chan graduated from Chungzhan Medical College in Guangzhou, China and then earne...

    journal_title:Future medicinal chemistry

    pub_type: 历史文章,面试

    doi:10.4155/fmc.12.171

    authors: Chan CC

    更新日期:2012-11-01 00:00:00

  • The specific role of O6-methylguanine-DNA methyltransferase inhibitors in cancer chemotherapy.

    abstract::The DNA repair protein, O6-methylguanine DNA methyltransferase (MGMT), can confer resistance to guanine O6-alkylating agents. Therefore, inhibition of resistant MGMT protein is a practical approach to increase the anticancer effects of such alkylating agents. Numerous small molecule inhibitors were synthesized and exh...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2018-0069

    authors: Sun G,Zhao L,Zhong R,Peng Y

    更新日期:2018-08-01 00:00:00

  • Butterfly structure: a scaffold of therapeutic importance.

    abstract::Graphical abstract [Formula: see text]. ...

    journal_title:Future medicinal chemistry

    pub_type: 社论

    doi:10.4155/fmc-2019-0313

    authors: Choudhary S,Silakari O

    更新日期:2020-02-01 00:00:00

  • Tuning heavy metal compounds for anti-tumor activity: is diversity the key to ruthenium's success?

    abstract::This review aims to bring the reader up to date with the more recent ruthenium compounds that have been synthesized and tested for their cytotoxicity. The chemistry of these transition metal complexes will be introduced and the basic principles that govern their common behavior outlined. The recent history of establis...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.09.25

    authors: Page SM,Boss SR,Barker PD

    更新日期:2009-06-01 00:00:00

  • Design, synthesis and biological evaluation of chromenopyrimidines as potential cytotoxic agents.

    abstract:AIM:The design and synthesis of chromenopyrimidines as microtubule destabilizing agents. MATERIALS & METHODS:Novel chromenopyrimidines and chromenotriazolopyrimidines were prepared and evaluated for their cytotoxicity against MCF-7 cell line. The most potent compound was tested for its possible effect on tubulin inhib...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0324

    authors: El-Bakhshawangy NM,El-Nassan HB,Kassab AE,Taher AT

    更新日期:2018-06-01 00:00:00

  • Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.

    abstract::Fingolimod (FTY720) is a first-in-class, orally active, sphingosine 1-phosphate (S1P)-receptor modulator with a structure closely related to sphingosine. The compound was discovered by chemical modification of a natural product, myriocin. Phosphorylated form of FTY720 acts as a functional antagonist at S1P receptor ty...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.25

    authors: Chiba K,Adachi K

    更新日期:2012-04-01 00:00:00

  • Recent development in acetyl-CoA carboxylase inhibitors and their potential as novel drugs.

    abstract::Acetyl-CoA carboxylase (ACC), a critical enzyme in the regulation of fatty acid synthesis and metabolism, has emerged as an attractive target for a plethora of emerging diseases, such as diabetes mellitus, nonalcoholic fatty liver disease, cancer, bacterial infections and so on. With decades of efforts in medicinal ch...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0312

    authors: Wu X,Huang T

    更新日期:2020-03-01 00:00:00

  • Pseudomonas aeruginosa: targeting cell-wall metabolism for new antibacterial discovery and development.

    abstract::Pseudomonas aeruginosa is a leading cause of hospital-acquired infections and is resistant to most antibiotics. With therapeutic options against P. aeruginosa dwindling, and the lack of new antibiotics in advanced developmental stages, strategies for preserving the effectiveness of current antibiotics are urgently req...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0017

    authors: Lamers RP,Burrows LL

    更新日期:2016-06-01 00:00:00

  • The promise and current status of CDK12/13 inhibition for the treatment of cancer.

    abstract::CDK12 and CDK13 are Ser/Thr protein kinases that regulate transcription and co-transcriptional processes. Genetic silencing of CDK12 is associated with genomic instability in a variety of cancers, including difficult-to-treat breast, ovarian, colorectal, brain and pancreatic cancers, and is synthetic lethal with PARP,...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0240

    authors: Tadesse S,Duckett DR,Monastyrskyi A

    更新日期:2021-01-01 00:00:00

  • Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus(®) library.

    abstract::The current state of antimalarial drug resistance emphasizes the need for new therapies with novel modes of action that will add a significant benefit compared with current standards. In this regard, high throughput phenotypic whole-cell screening aids the discovery of novel antiplasmodial scaffolds that are inherentl...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.12.176

    authors: Paquet T,Gordon R,Waterson D,Witty MJ,Chibale K

    更新日期:2012-12-01 00:00:00

  • Dual-pharmacology muscarinic antagonist and β₂ agonist molecules for the treatment of chronic obstructive pulmonary disease.

    abstract::Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the world today. Bronchodilators, particularly muscarinic antagonists and β(2) agonists, are recommended for patients with moderate to severe COPD. Dual-pharmacology muscarinic antagonist- β(2) agonist (MABA) molecules present an exc...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.11.106

    authors: Hughes AD,Jones LH

    更新日期:2011-10-01 00:00:00

  • Gallium-containing anticancer compounds.

    abstract::There is an ever pressing need to develop new drugs for the treatment of cancer. Gallium nitrate, a group IIIa metal salt, inhibits the proliferation of tumor cells in vitro and in vivo and has shown activity against non-Hodgkin's lymphoma and bladder cancer in clinical trials. Gallium can function as an iron mimetic ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.12.69

    authors: Chitambar CR

    更新日期:2012-06-01 00:00:00

  • DYRK1A inhibition as potential treatment for Alzheimer's disease.

    abstract::In total, 47,500,000 people worldwide are affected by dementia and this number is estimated to double by 2030 and triple within 2050 resulting in a huge burden on public health. Alzheimer's disease (AD), a progressive neurodegenerative disorder, is the most common cause of dementia, accounting for 60-70% of all the ca...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2016-0013

    authors: Stotani S,Giordanetto F,Medda F

    更新日期:2016-04-01 00:00:00

  • Chemokine receptor modeling: an interdisciplinary approach to drug design.

    abstract::Chemokines and their receptors are integral components of the immune response, regulating lymphocyte development, homing and trafficking, and playing a key role in the pathophysiology of many diseases. Chemokine receptors have, therefore, become the target for both small-molecule, peptide and antibody therapeutics. Ch...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.13.194

    authors: Fricker SP,Metz M

    更新日期:2014-01-01 00:00:00

  • Anti-inflammatory indomethacin analogs endowed with preferential COX-2 inhibitory activity.

    abstract:AIM:The undeniable indomethacin potency has always suffered serious obstacles such as gastric damage. Continuous attempts to develop potent yet safe indomethacin analogs have never ceased. RESULTS:Herein are new indole derivatives 4a-h and 5a-c, which were synthesized via Fisher indole reaction, evaluated for both the...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2018-0224

    authors: Amin NH,El-Saadi MT,Hefny AA,Abdelazeem AH,Elshemy HA,Abdellatif KR

    更新日期:2018-12-06 00:00:00

  • Structural and functional insight of New Delhi Metallo β-lactamase-1 variants.

    abstract::New Delhi Metallo β-lactamase-1 (NDM-1) is a member of the Metallo-β-lactamase family, capable of catalyzing the hydrolysis of all β-lactam antibiotics. The rapid dissemination of NDM producers, 'superbugs', has become a worldwide concern to health workers. Seventeen different variants of NDM have been reported so far...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0143

    authors: Khan S,Ali A,Khan AU

    更新日期:2018-01-01 00:00:00

  • The search for a common structural moiety among selected pharmacological correctors of the mutant CFTR chloride channel.

    abstract:BACKGROUND:The F508del mutation impairs the trafficking of CFTR from endoplasmic reticulum to plasma membrane and is responsible of a severe form of cystic fibrosis. Trafficking can be improved by small organic molecules called 'correctors'. MATERIALS & METHODS:By different synthetic ways, we prepared 4-chloroanisole ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc.14.118

    authors: Nieddu E,Pollarolo B,Mazzei MT,Anzaldi M,Schenone S,Pedemonte N,Pesce E,Galietta LJ,Mazzei M

    更新日期:2014-01-01 00:00:00

  • Natural products and ion channel pharmacology.

    abstract::An accelerated rate of natural-product discovery is critical for the future of ion channel pharmacology. For the full potential of natural products to be realized, an interdisciplinary initiative is required that combines chemical ecology and ion channel physiology. A prime source of future drug leads targeted to ion ...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.10.31

    authors: Teichert RW,Olivera BM

    更新日期:2010-05-01 00:00:00

  • An unexpected discovery toward novel membrane active sulfonyl thiazoles as potential MRSA DNA intercalators.

    abstract::Aim: With the increasing emergence of drug-resistant bacteria, the need for new antimicrobial agents has become extremely urgent. This work was to develop sulfonyl thiazoles as potential antibacterial agents. Results & methodology: Novel hybrids of sulfonyl thiazoles were developed from commercial acetanilide and acet...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2019-0303

    authors: Hu YY,Wang J,Li TJ,Yadav Bheemanaboina RR,Ansari MF,Cheng Y,Zhou CH

    更新日期:2020-10-01 00:00:00

  • Rho kinase as a target for cerebral vascular disorders.

    abstract::The development of novel pharmaceutical treatments for disorders of the cerebral vasculature is a serious unmet medical need. These vascular disorders are typified by a disruption in the delicate Rho signaling equilibrium within the blood vessel wall. In particular, Rho kinase overactivation in the smooth muscle and e...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc.15.45

    authors: Bond LM,Sellers JR,McKerracher L

    更新日期:2015-01-01 00:00:00

  • Enhancing anticancer activity through the combination of bioreducing agents and triterpenes.

    abstract:AIM:Triterpenes are natural compounds, whose wide biological activity predestines them for application as promising new chemotherapeutics. In this paper, we report the results of our investigations into the substitution of oleanolic acid with aromatic and nitroaromatic moieties acting as bioreducing agents. RESULTS:Th...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2017-0154

    authors: Bednarczyk-Cwynar B,Ruszkowski P,Jarosz T,Krukiewicz K

    更新日期:2018-03-01 00:00:00

  • Zinc complexation improves angiotensin II receptor type 1 blockade and in vivo antihypertensive activity of telmisartan.

    abstract::Background: Angiotensin II receptor blockers were designed as therapeutic agents to block the binding site of the angiotensin II receptor type 1 (AT1R). Methodology: The structure of telmisartan was modified by coordination to the biometal Zn(II), resulting in the compound ZnTelm. Its antihypertensive activity and cel...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章

    doi:10.4155/fmc-2020-0093

    authors: Martínez VR,Aguirre MV,Todaro JS,Lima AM,Stergiopulos N,Ferrer EG,Williams PA

    更新日期:2021-01-01 00:00:00

  • Synthesis & antitumor activity of epothilones B and D and their analogs.

    abstract::Epothilone is a newly developed antitumor drug; its antitumor principle is to stop the cell cycle by binding to tubulin in tumor cells, promoting tubulin polymerization, inhibiting depolymerization of microtubules, and ultimately inducing apoptosis. There are many analogs of epothilone, such as epothilone B, epothilon...

    journal_title:Future medicinal chemistry

    pub_type: 杂志文章,评审

    doi:10.4155/fmc-2017-0320

    authors: Cheng H,Huang G

    更新日期:2018-06-01 00:00:00

  • Interview with Solomon Nwaka.

    abstract::Solomon Nwaka was born in Nigeria and grew up seeing at first hand the impact of neglected diseases. His research efforts have taken him across the globe, in both the developed and developing world. Following posts in academia, industry and at the Medicines for Malaria Venture, he is now at the WHO where he is engaged...

    journal_title:Future medicinal chemistry

    pub_type: 面试

    doi:10.4155/fmc.11.99

    authors: Nwaka S

    更新日期:2011-09-01 00:00:00